Most people with lupus have it affect the skin. The types of rashes can be divided into two large groups. First, when lupus affects the skin with problems only seen in lupus, it’s called cutaneous ...

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at ...

A Phase 2b Study of IMVT-1402* in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) with or without systemic manifestations.

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus ...

Patients with cutaneous lupus erythematosus (CLE) experienced improved symptoms with iberdomide, a cereblon modulator, added to standard lupus medications, particularly in subacute and chronic cases. ...

Litifilimab significantly improved skin disease activity in CLE, with a CLASI-A score difference from placebo of up to -33.4 percentage points. The Food and Drug Administration (FDA) has granted ...

Objectives Fatigue is one of the most common and debilitating symptoms experienced by patients with systemic lupus erythematosus (SLE). Previous studies revealed the association of fatigue with ...

A patient developed granulomatosis with polyangiitis (GPA), a type of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), following a long-standing history of systemic lupus ...

Background/objective To reduce the risk of hydroxychloroquine (HCQ)-induced retinopathy, the American Academy of ...